Reduction of share capital registered by the Swedish Companies Registration Office
![](https://mb.cision.com/Public/4632/Cnct_FtrdImg_Dj_4020007/a7c8a18ff7a6a34a_featured.jpg)
Stockholm, July 31, 2024 - Intervacc AB (publ) announces that the reduction of share capital and nominal value, decided by the Annual General Meeting on May 15, 2024, has been registered by the Swedish Companies Registration Office. After registration, the nominal value is 0.20 SEK per share and the share capital amounts to 15,147,252.80 SEK after the reduction. The number of shares remains unchanged at 75,736,264.
For more information please contact:
Jonas Sohlman, CEO
E-mail: jonas.sohlman@intervacc.se
Phone: +46 (0)8 120 10 600
The information was submitted for publication, through the agency of the contact person set out above on July 31, 2024, 10.00 CET.
About Intervacc
Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10